Bruker reports Q1 EPS 47c, consensus 44c

Reports Q1 revenue $801.4M, consensus $772.47M. Frank H. Laukien, Bruker’s (BRKR) President and CEO, commented: “Bruker had a solid start to 2025 with double-digit reported and CER revenue growth, 5.1% organic revenue growth in our BSI segment, and better operating margin performance than expected – all on strong execution, despite uncertainties in key markets. In Q1 and April, we launched key products in spatial biology, NMR, microbiology and molecular diagnostics. Proactive cost management helped drive organic operating margin expansion, partially offsetting the expected Q1 margin headwinds from our strategic acquisitions in Q2 of 2024.”